AstraZeneca Pharma gets nod to import, market Durvalumab Solution

17 Mar 2026 Evaluate

AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India, to import for sale and distribution of Durvalumab Solution for Infusion 120 mg/2.4 mL and 500 mg/10 mL (Brand Name: Imfinzi) for an additional indication.

Through this approval, Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC) who have not received prior systemic therapy. The receipt of this permission paves way for the marketing of Durvalumab Solution for Infusion 120 mg/2.4 mL and 500 mg/10 mL (Imfinzi) in India for the specified additional indication, subject to the receipt of related statutory approvals, if any.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.

Astrazeneca Pharma I Share Price

8495.70 50.40 (0.60%)
18-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1778.75
Dr. Reddys Lab 1294.25
Cipla 1268.20
Zydus Lifesciences 898.75
Lupin 2302.55
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×